Diaceutics Enhances PMx Contract with Partner Therapeutics for BIZENGRI®

Diaceutics ( (GB:DXRX) ) has shared an announcement.

Diaceutics PLC has enhanced its PMx Promotional Partner Contract with Partner Therapeutics, Inc., following the licensing of US rights to the oncology precision medicine BIZENGRI® (zenocutuzumab – zbco). The new agreement, worth up to £11.5 million, allows Diaceutics to leverage its DXRX platform to support the commercialization of BIZENGRI®, aiming to accelerate the adoption of precision medicines and maximize patient treatment opportunities. The contract, which replaces a previous agreement, is expected to generate significant recurring service revenues and reflects a strategic shift towards guaranteed service fees, enhancing Diaceutics’ market positioning in precision medicine.

More about Diaceutics

Diaceutics PLC is a leading technology and solutions provider in the pharma and biotech industry, offering end-to-end commercialization solutions for precision medicines through data analytics, scientific, and advisory services enabled by their DXRX platform, The Diagnostics Network®. They focus on ensuring patients receive the right test and therapy to positively impact their disease outcomes.

YTD Price Performance: -0.22%

Technical Sentiment Signal: Sell

Current Market Cap: $137.8M

Find detailed analytics on DXRX stock on TipRanks’ Stock Analysis page.